Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Inc. (POAI) Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital
  Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY .   The STREAMWAY System transforms the collection, measurement and disposal of healthcare waste fluid making it safer, easier and environmentally
View HTML
Toggle Summary Predictive Oncology Inc. Announces Proposed Public Offering of Common Stock
MINNEAPOLIS , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the
View HTML
Toggle Summary Predictive Oncology Inc. Announces Repayment or Extension of Promissory Notes due September 28, 2019
MINNEAPOLIS , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced that its secured promissory notes that were due September 28, 2019 have been repaid or extended. On September 27, 2019 , the Company repaid the remaining
View HTML
Toggle Summary Coverage Initiated for Predictive Oncology via NetworkNewsWire
NEW YORK , Sept. 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Predictive Oncology (NASDAQ: POAI), an innovative company focused on the use of data and artificial intelligence (AI) to develop personalized cancer therapies and improve patient outcome, today announces it has selected the corporate
View HTML
Toggle Summary Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Management to Host Conference Call to Review Financial Results and Provide Corporate Update at 5:30PM Today MINNEAPOLIS , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional
View HTML
Toggle Summary Predictive Oncology to Report Second Quarter 2019 Financial Results and Provide Company Update on Monday, August 19, 2019
Conference Call to be held August 19, 2019, at 4:30pm Eastern Time MINNEAPOLIS , Aug. 15, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. , (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the
View HTML
Toggle Summary Predictive Oncology’s Skyline Medical Division Expands Its Asian Market Share with First-Ever Orders of STREAMWAY Systems in India
MINNEAPOLIS , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology, Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), today announced its Skyline Medical division has received its first order from India for four machines to be sold to local hospitals.
View HTML
Toggle Summary Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance the Diagnosis of Thyroid Cancer via AI-Driven Models
Three Most Recent Pittsburgh-Based Development Partnerships Demonstrate Value and Recognition for Helomics’ AI-Driven, Patient Derived “Multi-Omic” Discovery Platform MINNEAPOLIS , July 30, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a
View HTML
Toggle Summary Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data and Artificial Intelligence-Driven Approach to Treating Ovarian Cancer
PITTSBURGH , July 18, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products
View HTML
Toggle Summary Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement with ChemImage to Expand Personalized Medicine to Prostate Cancer Prognosis and Treatment
MINNEAPOLIS, Minn ., June 26, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has signed a collaborative research agreement
View HTML